Drew Ranieri
Stock Analyst at Morgan Stanley
(0.64)
# 3,647
Out of 5,180 analysts
170
Total ratings
32.79%
Success rate
-25.91%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $12.63 | +82.11% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $86.16 | +16.06% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $10.88 | +93.01% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $2.37 | +153.16% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $328.59 | +35.43% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $9.42 | +186.62% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $1.34 | +497.01% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $13.75 | +60.00% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $13.15 | -39.14% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $3.84 | +2,048.44% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $25.37 | +49.78% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $56.36 | +70.33% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $14.01 | +85.58% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $157.23 | +87.62% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $119.61 | +134.09% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $9.13 | -45.24% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $16.80 | +316.67% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $460.99 | -34.92% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $12.63
Upside: +82.11%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $86.16
Upside: +16.06%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $10.88
Upside: +93.01%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $2.37
Upside: +153.16%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $328.59
Upside: +35.43%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $9.42
Upside: +186.62%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $1.34
Upside: +497.01%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $13.75
Upside: +60.00%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $13.15
Upside: -39.14%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $3.84
Upside: +2,048.44%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $25.37
Upside: +49.78%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $56.36
Upside: +70.33%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $14.01
Upside: +85.58%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $157.23
Upside: +87.62%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $119.61
Upside: +134.09%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $9.13
Upside: -45.24%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $16.80
Upside: +316.67%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $460.99
Upside: -34.92%